Creative Financial Designs Inc Immunovant, Inc. Transaction History

Creative Financial Designs Inc

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 01, 2022	SELL	$3.38 - $5.65 $47,201 - $78,902	-13,965 Closed	0 $0
Q1 2022 Apr 15, 2022	BUY	$5.06 - $8.77 $7,665 - $13,286	1,515 Added 12.17%	13,965 $77,000
Q4 2021 Jan 26, 2022	SELL	$7.33 - $9.32 $10,936 - $13,905	-1,492 Reduced 10.7%	12,450 $106,000
Q3 2021 Oct 08, 2021	SELL	$7.01 - $11.37 $175 - $284	-25 Reduced 0.18%	13,942 $121,000
Q2 2021 Jul 27, 2021	BUY	$9.4 - $16.85 $45,825 - $82,143	4,875 Added 53.62%	13,967 $148,000
Q1 2021 Apr 19, 2021	BUY	$13.08 - $49.6 $66,773 - $253,208	5,105 Added 128.04%	9,092 $146,000
Q4 2020 Jan 08, 2021	BUY	$36.36 - $52.71 $25,706 - $37,265	707 Added 21.55%	3,987 $184,000
Q3 2020 Oct 06, 2020	BUY	$22.61 - $38.9 $74,160 - $127,592	3,280 New	3,280 $115,000

211

66.9M

2.3M

631K

Ticker IMVT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 129,077,000
Market Cap $3.55B
Description
Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of mya...

Get notified when there are updates to the investment portfolio of Creative Financial Designs Inc , based on Form 13F filings with the SEC.

Stay updated on Creative Financial Designs Inc with notifications on news.